SUSAN HILSENBECK to Drug Administration Schedule
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Drug Administration Schedule.
Connection Strength
0.068
-
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
Score: 0.023
-
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
Score: 0.013
-
Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant. 2000 Sep; 26(6):601-5.
Score: 0.010
-
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res. 1999 Mar 01; 59(5):1049-53.
Score: 0.009
-
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996 Apr; 14(4):1128-35.
Score: 0.007
-
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993 Nov; 11(11):2194-204.
Score: 0.006